Drugs / BIBT 1011 BS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02182037 | Aug → Sep 2001 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIBT 1011 BS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02182037 ↗ |
| Known as | BIBT 986 BS | “A study to assess safety, pharmacokinetics and the effect of BIBT 986 BS, given as BIBT 1011 BS, on coagulation parameters.” NCT02182037 ↗ |
| Route | Oral | “Single Oral Administration of 1, 5, 10, 30, 100, 200 and 400 mg BIBT 1011 BS as Drinking Solution” NCT02182037 ↗ |